目的:观察罗沙司他治疗腹膜透析(PD)肾性贫血患者的有效性及安全性。方法:回顾性分析2019年6月至2020年2月国家肾脏疾病临床医学研究中心口服罗沙司他的PD患者为罗沙司他组,按照1∶1比例随机选取皮下注射重组人促红细胞生成素(rHuEPO)...目的:观察罗沙司他治疗腹膜透析(PD)肾性贫血患者的有效性及安全性。方法:回顾性分析2019年6月至2020年2月国家肾脏疾病临床医学研究中心口服罗沙司他的PD患者为罗沙司他组,按照1∶1比例随机选取皮下注射重组人促红细胞生成素(rHuEPO)的PD患者为对照组,分析两组患者的一般资料、血红蛋白(Hb)、铁代谢指标、炎症指标、脂代谢指标、不良反应等,所有患者至少完成随访时间1年。结果:共收集罗沙司他组34例,对照组34例,两组患者基线临床资料及实验室指标无统计学差异,罗沙司他组基线平均Hb(85.3±11.4) g/L。两组患者经治疗后使Hb维持在110~120 g/L,1年后Hb较基线值均显著升高,两组患者Hb无明显差异(P=0.081),但与对照组相比,罗沙司他组患者的铁代谢指标、脂代谢指标、炎症指标、平均动脉压(MAP)、空腹血糖优于对照组(P<0.05)。与基线相比,罗沙司他治疗1年后血清铁、转铁蛋白饱和度(TSAT)和铁蛋白降低,总铁结合力升高(P<0.05)。罗沙司他组患者不同炎症状态下Hb无明显变化,而对照组炎症指标高的患者Hb更低(P<0.05)。罗沙司他组血压升高发生率低于对照组(0 vs 23.5%,P=0.005)。结论:罗沙司他治疗PD肾性贫血疗效不低于rHuEPO,其疗效不受炎症状态影响,且可改善脂代谢、糖代谢和炎症指标,对血压影响较小,故具有较好的疗效及安全性。展开更多
BACKGROUND Gestational anemia is a serious public health problem that affects pregnant women worldwide.Pregnancy conditions and outcomes might be associated with the presence of gestational anemia.This study investiga...BACKGROUND Gestational anemia is a serious public health problem that affects pregnant women worldwide.Pregnancy conditions and outcomes might be associated with the presence of gestational anemia.This study investigated the association of pregnancy characteristics with anemia,exploring the potential etiology of the disease.AIM To assess the association of pregnancy parameters with gestational anemia.METHODS A nested case-control study was conducted based on the Chinese Pregnant Women Cohort Study-Peking Union Medical College Project(CPWCS-PUMC).A total of 3172 women were included.Patient characteristics and gestational anemia occurrence were extracted,and univariable and multivariable logistic regression models were used to analyze the association of pregnancy parameters with gestational anemia.RESULTS Among the 3172 women,14.0% were anemic,46.4% were 25-30 years of age,21.9%resided in eastern,15.7%in middle,12.4%in western 18.0% in southern and 32.0%in northern regions of China.Most women(65.0%)had a normal prepregnancy body mass index.Multivariable analysis found that the occurrence of gestational anemia was lower in the middle and western regions than that in the eastern region[odds ratio(OR)=0.406,95%confidence interval(CI):0.309-0.533,P<0.001],higher in the northern than in the southern region(OR=7.169,95% CI:5.139-10.003,P<0.001),lower in full-term than in premature births(OR=0.491,95% CI:0.316-0.763,P=0.002),and higher in cases with premature membrane rupture(OR=1.404,95% CI:1.051-1.876,P=0.02).CONCLUSION Gestational anemia continues to be a health problem in China,and geographical factors may contribute to the situation.Premature birth and premature membrane rupture may be associated with gestational anemia.Therefore,we should vigorously promote local policy reformation to adapt to the demographic characteristics of at-risk pregnant women,which would potentially reduce the occurrence of gestational anemia.展开更多
文摘目的:观察罗沙司他治疗腹膜透析(PD)肾性贫血患者的有效性及安全性。方法:回顾性分析2019年6月至2020年2月国家肾脏疾病临床医学研究中心口服罗沙司他的PD患者为罗沙司他组,按照1∶1比例随机选取皮下注射重组人促红细胞生成素(rHuEPO)的PD患者为对照组,分析两组患者的一般资料、血红蛋白(Hb)、铁代谢指标、炎症指标、脂代谢指标、不良反应等,所有患者至少完成随访时间1年。结果:共收集罗沙司他组34例,对照组34例,两组患者基线临床资料及实验室指标无统计学差异,罗沙司他组基线平均Hb(85.3±11.4) g/L。两组患者经治疗后使Hb维持在110~120 g/L,1年后Hb较基线值均显著升高,两组患者Hb无明显差异(P=0.081),但与对照组相比,罗沙司他组患者的铁代谢指标、脂代谢指标、炎症指标、平均动脉压(MAP)、空腹血糖优于对照组(P<0.05)。与基线相比,罗沙司他治疗1年后血清铁、转铁蛋白饱和度(TSAT)和铁蛋白降低,总铁结合力升高(P<0.05)。罗沙司他组患者不同炎症状态下Hb无明显变化,而对照组炎症指标高的患者Hb更低(P<0.05)。罗沙司他组血压升高发生率低于对照组(0 vs 23.5%,P=0.005)。结论:罗沙司他治疗PD肾性贫血疗效不低于rHuEPO,其疗效不受炎症状态影响,且可改善脂代谢、糖代谢和炎症指标,对血压影响较小,故具有较好的疗效及安全性。
文摘BACKGROUND Gestational anemia is a serious public health problem that affects pregnant women worldwide.Pregnancy conditions and outcomes might be associated with the presence of gestational anemia.This study investigated the association of pregnancy characteristics with anemia,exploring the potential etiology of the disease.AIM To assess the association of pregnancy parameters with gestational anemia.METHODS A nested case-control study was conducted based on the Chinese Pregnant Women Cohort Study-Peking Union Medical College Project(CPWCS-PUMC).A total of 3172 women were included.Patient characteristics and gestational anemia occurrence were extracted,and univariable and multivariable logistic regression models were used to analyze the association of pregnancy parameters with gestational anemia.RESULTS Among the 3172 women,14.0% were anemic,46.4% were 25-30 years of age,21.9%resided in eastern,15.7%in middle,12.4%in western 18.0% in southern and 32.0%in northern regions of China.Most women(65.0%)had a normal prepregnancy body mass index.Multivariable analysis found that the occurrence of gestational anemia was lower in the middle and western regions than that in the eastern region[odds ratio(OR)=0.406,95%confidence interval(CI):0.309-0.533,P<0.001],higher in the northern than in the southern region(OR=7.169,95% CI:5.139-10.003,P<0.001),lower in full-term than in premature births(OR=0.491,95% CI:0.316-0.763,P=0.002),and higher in cases with premature membrane rupture(OR=1.404,95% CI:1.051-1.876,P=0.02).CONCLUSION Gestational anemia continues to be a health problem in China,and geographical factors may contribute to the situation.Premature birth and premature membrane rupture may be associated with gestational anemia.Therefore,we should vigorously promote local policy reformation to adapt to the demographic characteristics of at-risk pregnant women,which would potentially reduce the occurrence of gestational anemia.
